Jan 16, 2024
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
Jan 12, 2024
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
Feb 23, 2021
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
Feb 10, 2021
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
Nov 23, 2020
Halozyme Raises Full Year 2020 Guidance
Nov 02, 2020
Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance
Sep 10, 2020
Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis
Sep 02, 2020
Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference
Aug 04, 2020
Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference
Jul 29, 2020
Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call
Jun 29, 2020
Halozyme Announces Roche Receives FDA Approval For Phesgo(TM) (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer
Jun 17, 2020
Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference
Jun 13, 2020
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
May 14, 2020
Halozyme To Receive $15 Million Milestone Payment From Janssen
May 11, 2020
Halozyme Reports First Quarter 2020 Results
May 07, 2020
Halozyme To Present At The Bank Of America Securities 2020 Healthcare Conference
May 01, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
Apr 30, 2020
Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 26, 2020
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 03, 2020
Halozyme Announces Change Of Location Of Annual Stockholders' Meeting